| Similar Articles |
|---|
 |
The Motley Fool
June 24, 2005
Brian Gorman |
Salix's Strange Deal Salix announced that it will buy Inkine in an all-stock acquisition valued at $190 million. At first glance, the two companies appear to be a good strategic fit, since both specialize in marketing gastrointestinal drugs. However, the agreement seems to have more weaknesses than strengths.   |
The Motley Fool
February 24, 2011
Brian D. Pacampara |
Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan. |
The Motley Fool
May 10, 2011
Frank Vinluan |
Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market? |
BusinessWeek
May 22, 2006
Gene G. Marcial |
Why Patterson May Get Its Smile Back Analysts say the No. 2 supplier of products to dentists and dental labs in North America shows growth in sales and earnings. And its valuation makes it a prime candidate for a buyout. Investors, take note. |
The Motley Fool
February 25, 2011
Brian Orelli |
When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections? |
The Motley Fool
November 30, 2010
Brian Orelli |
Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me. |
BusinessWeek
January 19, 2004 |
Tempting Buys In Oil Drilling And Broadband Gear Some stock picks. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
October 8, 2010
Travis Hoium |
99 Cents Only Stores Shares Plunged: What You Need to Know 99 Cents Only Stores shares dropped 10% in early morning trading after revenue missed analysts expectations. Is this meaningful? Or just another movement? |
The Motley Fool
December 20, 2011
Brian D. Pacampara |
Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor. |
